- Home
- ENLV vs BIII Comparison
ENLV vs BIII Comparison
Compare ENLV & BIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.82
Company Overview
Basic Information| Metric | ENLV | BIII |
|---|---|---|
| Founded | 2005 | 2025 |
| Country | Israel | Hong Kong |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 227.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENLV | BIII |
|---|---|---|
| Price | $0.82 | $9.88 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 756.6K | 50.2K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $9.83 |
| 52 Week High | $2.10 | $9.97 |
Technical Indicators
Market Signals| Indicator | ENLV | BIII |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 47.43 |
| Support Level | $0.81 | $9.83 |
| Resistance Level | $1.19 | $9.93 |
| Average True Range (ATR) | 0.11 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.06 | 83.33 |
Price Performance
Historical Comparison ENLV
BIII
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About BIII Black Spade Acquisition III Co Class A Ordinary Shares
Black Spade Acquisition III Co is a blank check company.